Human body have T cells in the immune system which protect the body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). In Cancer immunotherapy, these T cells boosts the antitumor efficacy of T cells by release inhibition of Immune checkpoints. It also expands the adaptive immunity by promote the adoptive transfer of T cells. These T cells are genetically equipped with chimeric antigen receptors (CARs) or TCRs . It shown phenomenol effectiveness in treating some hematological malignancies. Whereas the efficacy of Engineered T cells in treating solid tomors is far from satisfactory. In this review, we are going to summarize how the genetically engineered T cells are developed and what are the recent studies now investigated for genetically engineered T cells for Tumor immunotherapy and also discuss about the strategies for improving the performance of these T cells for the fight against Tumor
